F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer.
作者信息
Borm Frank Johannes, De Langen Adrianus Johannes
机构信息
Department of Thoracic Oncology, Netherlands Cancer Institute Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
出版信息
J Thorac Dis. 2020 Jul;12(7):3883-3885. doi: 10.21037/jtd.2020.03.12.
Abstract
摘要
相似文献
1
F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描预测非小细胞肺癌患者肿瘤程序性死亡受体配体1表达及对程序性死亡受体1/程序性死亡受体配体1阻断治疗的反应
J Thorac Dis. 2020 Jul;12(7):3883-3885. doi: 10.21037/jtd.2020.03.12.
2
F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.氟代脱氧葡萄糖正电子发射断层扫描代谢-形态学容积比预测非小细胞肺癌 PD-L1 肿瘤表达和对 PD-1 阻断的反应。
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868. doi: 10.1007/s00259-019-04348-x. Epub 2019 Jun 18.
3
Association Between PD-L1 Expression and Metabolic Activity on F-FDG PET/CT in Patients with Small-sized Lung Cancer.小肺癌患者F-FDG PET/CT上PD-L1表达与代谢活性之间的关联
Anticancer Res. 2017 Dec;37(12):7073-7082. doi: 10.21873/anticanres.12180.
4
Relationship between the expression of PD-1/PD-L1 and F-FDG uptake in bladder cancer.PD-1/PD-L1 的表达与膀胱癌 F-FDG 摄取之间的关系。
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):848-854. doi: 10.1007/s00259-018-4208-8. Epub 2019 Jan 9.
5
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.非小细胞肺癌中PD-L1表达与FDG PET/CT代谢参数及临床病理特征的相关性
EJNMMI Res. 2020 May 19;10(1):51. doi: 10.1186/s13550-020-00639-9.
6
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.对于适合进行 upfront 手术的非小细胞肺癌（NSCLC）患者，FDG-PET 上的代谢信息与免疫标志物组织表达的相关性。
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.
7
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.18F-FDG PET/CT在非小细胞肺癌患者中的应用：一种潜在的免疫治疗反应预测生物标志物。
Nucl Med Commun. 2019 Aug;40(8):802-807. doi: 10.1097/MNM.0000000000001025.
8
Retrospective analysis of the prognostic value of PD-L1 expression and F-FDG PET/CT metabolic parameters in colorectal cancer.结直肠癌中PD-L1表达及F-FDG PET/CT代谢参数预后价值的回顾性分析
J Cancer. 2020 Feb 25;11(10):2864-2873. doi: 10.7150/jca.38689. eCollection 2020.
9
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.肺鳞癌中肿瘤相关免疫与 18F-FDG-PET 的相关性。
Lung Cancer. 2018 May;119:71-77. doi: 10.1016/j.lungcan.2018.03.001. Epub 2018 Mar 16.
10
Metabolic activity by F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.F-FDG-PET/CT 代谢活性可预测先前治疗的 NSCLC 患者接受 nivolumab 后的早期应答。
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66. doi: 10.1007/s00259-017-3806-1. Epub 2017 Aug 21.
本文引用的文献
1
Radiomics of F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy.F-FDG PET/CT图像的放射组学可预测晚期非小细胞肺癌患者接受检查点阻断免疫治疗的临床获益。
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1168-1182. doi: 10.1007/s00259-019-04625-9. Epub 2019 Dec 5.
2
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）上的基线代谢肿瘤负荷可预测接受免疫检查点抑制剂治疗的晚期非小细胞肺癌（NSCLC）患者的预后。
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1147-1157. doi: 10.1007/s00259-019-04615-x. Epub 2019 Nov 21.
3
F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.氟代脱氧葡萄糖正电子发射断层扫描代谢-形态学容积比预测非小细胞肺癌 PD-L1 肿瘤表达和对 PD-1 阻断的反应。
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868. doi: 10.1007/s00259-019-04348-x. Epub 2019 Jun 18.
4
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.18F-FDG PET/CT在非小细胞肺癌患者中的应用：一种潜在的免疫治疗反应预测生物标志物。
Nucl Med Commun. 2019 Aug;40(8):802-807. doi: 10.1097/MNM.0000000000001025.
5
Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.肿瘤坏死与肺腺癌中的 PD-L1 和 PD-1 表达相关。
Acta Oncol. 2019 Aug;58(8):1087-1094. doi: 10.1080/0284186X.2019.1598575. Epub 2019 Apr 19.
6
Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer.起始 PD-1 抑制剂后早期炎症细胞因子升高对预测非小细胞肺癌患者疗效的影响。
Med Oncol. 2019 Mar 1;36(4):33. doi: 10.1007/s12032-019-1255-3.
7
Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.Zr-atezolizumab 成像作为一种非侵入性方法，用于评估 PD-L1 阻断在癌症中的临床反应。
Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.
8
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.全身 PD-1 和 PD-L1 正电子发射断层扫描在非小细胞肺癌患者中的应用。
Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.
9
Non-muscular myosin light chain kinase triggers intermittent hypoxia-induced interleukin-6 release, endothelial dysfunction and permeability.非肌球蛋白轻链激酶触发间歇性低氧诱导的白细胞介素-6 释放、内皮功能障碍和通透性。
Sci Rep. 2017 Oct 20;7(1):13664. doi: 10.1038/s41598-017-13268-5.
10
Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on F-fluorodeoxyglucose positron emission tomography/computed tomography.F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描显示的程序性细胞死亡配体1表达的肺癌的代谢特征
Cancer Med. 2017 Nov;6(11):2552-2561. doi: 10.1002/cam4.1215. Epub 2017 Oct 4.
Zotero 插件